Hengrui Pharma licenses GLP-1/GIP drug HRS-1596 to Novo Nordisk in deal worth up to USD 2.6 billion

• Jiangsu Hengrui Medicine entered a global licensing deal with Novo Nordisk for HRS-1596, an oral once-weekly GLP-1/GIP dual agonist candidate.
• Novo Nordisk gets exclusive rights outside mainland China, Hong Kong, Macau, and Taiwan to develop, manufacture, and commercialize the drug.
• Deal value totals up to USD 2.6 billion, including USD 300 million upfront and up to USD 2.3 billion in milestones.
• Hengrui also qualifies for royalties tied to net sales in the licensed territory.
• Closing is expected in Q4 2026, subject to U.S. antitrust clearance and other customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260929-12350036), on September 29, 2026, and is solely responsible for the information contained therein.